Educational Update: Toxic Anterior Segment Syndrome (TASS) - Awareness and Best Practices

Educational Update: Toxic Anterior Segment Syndrome (TASS) – Awareness and Best Practices

As part of our continued commitment to surgical excellence and patient safety, and in light of recent discussions, we are sharing an educational update on Toxic Anterior Segment Syndrome (TASS). Recently, a voluntary recall was issued for specific intraocular lenses (IOLs) following reported TASS cases. The issue was ultimately traced to a raw material from a third-party supplier. Enhanced quality assurance and inspection protocols have since been implemented, and the affected lenses have returned to market. While outbreaks remain rare, sporadic cases persist, reinforcing the need for continued vigilance.

Please note: the information below is intended solely for educational purposes and is not associated with any specific manufacturer, product, or recall.

What is TASS?

TASS is an acute, sterile postoperative inflammatory response involving the anterior segment, typically developing within 12 to 48 hours after surgery. It results from the introduction of non-infectious toxic substances into the anterior chamber and must be carefully distinguished from infectious endophthalmitis (Mamalis et al., 2006; Peck et al., 2010).

Common Causes:

Multiple risk factors have been identified (Mamalis, 201 O; Eydelman et al., 2012), including:

Residual detergents or enzymatic cleaning agents on instruments
Contaminated intraocular solutions or medications
Improper preparation, sterilization, or storage of instruments
Use of preservatives or toxic chemicals in the surgical field
Inadequate flushing of reusable cannulas or tubing
Contaminated IOLs, ophthalmic viscosurgical devices (OVDs), or packaging materials
Manufacturing processes (e.g., changes in raw materials, packaging, or sterilization
conditions) (FDA, 2022; Sengillo et al., 2020)
Clinical Presentation and Diagnosis

Typical signs include:

Marked anterior chamber inflammation with cell, flare, fibrin, and sometimes hypopyon
Iris damage, fixed dilated pupil, or secondary glaucoma in severe case
Absence of significant ocular pain (distinguishing from infectious endophthalmitis)
Diffuse limbus-to-limbus corneal edema

Infectious endophthalmitis often presents later (7-10 days postop) and requires antimicrobial treatment, whereas TASS demands immediate anti-inflammatory therapy. Diagnostic caution is essential. In uncertain cases, anterior chamber tap and culture may be warranted (Verma et al., 2024).

Management:

Initiate intensive topical corticosteroids promptly (Navas et al., 2019)
Topical NSAIDs can be considered as an adjunct in reducing inflammation and preventing or treating cystoid macular edema
Monitor daily for improvement
Consider anterior chamber washout in severe or refractory cases
lntravitreal antibiotics are not indicated unless an infectious cause is suspected
Manage sequelae such as glaucoma or endothelial loss as needed

Prevention Best Practices:

Strict adherence to sterilization protocols; avoid reusing disposable items
Ensure thorough rinsing of all surgical instruments
Avoid detergents with strong enzymatic activity or residue retention
Verify proper preparation, handling, and labeling of intraocular solutions and OVDs
Maintain traceability of surgical supplies in case of cluster analysis

In the event of multiple cases, a thorough root cause analysis should evaluate all materials (IOLs, OVDs, BSS), packaging, sterilization processes, and any vendor changes.

Ongoing internal audits, protocol reviews, and prompt reporting of suspected cases remain essential to patient safety.

We encourage all surgical teams to review their current practices and remain vigilant. If there is interest in broader educational engagement, the TASS Committee welcomes your participation.

Thank you for your dedication to surgical excellence and patient care.

Sincerely,

The Canadian TASS Committee
Canadian Ophthalmological Society

Adam Muzychuk MD, Annual Meeting Chair
Simon Holland MD, TASS Committee Chair
Rene Cabana, Consultant in Eye Care
Doug Morck, Professor and Chairman, Veterinarian, University of Calgary

References:

Mamalis, N., Edelhauser, H. F., Dawson, D. G., et al. (2006). Toxic anterior segment
syndrome. Journal of Cataract & Refractive Surgery, 32(2), 324-333.

Peck, C. M. C., Brubaker, J., Clouser, S., Danford, C., et al. (2010). Toxic anterior segment
syndrome: Common causes. Journal of Cataract & Refractive Surgery, 36(7), 1073-1077.

Navas, A., Hernandez-Bogantes, E., Naranjo, A., et al. (2019). Toxic anterior segment
syndrome: A review. Survey of Ophthalmology, 64(6), 77 4-786.

Eydelman, M. B., Tarver, M. E., Calogero, D., et al. (2012). FDA’s proactive TASS
program. Ophthalmology, 119(7), 1339-1346.

Verma, L., Malik, A., Maharana, P. K., Dada, T. (2024). Toxic anterior segment syndrome
(TASS): A review and update. Indian Journal of Ophthalmology, 72(1 ), 45-52.

Park, C. Y., Lee, J. K., Chuck, R. S. (2018). Toxic anterior segment syndrome-an updated
review. BMC Ophthalmology, 18(1 ), 276.

Sengillo, J. 0 ., Chen, Y., Garcia, D. P., et al. (2020). Postoperative endophthalmitis and TASS prophylaxis: 2020 update. Annals of Translational Medicine, 8(22), 1548.

Mamalis, N. (2010). Toxic anterior segment syndrome update. Journal of Cataract & Refractive Surgery, 36(7), 1077-1078.

U.S. Food and Drug Administration (FDA). (2022). Endotoxin Testing Recommendations for Single-Use lntraocular Ophthalmic Devices. Available at:
https://www.fda.gov/media/162753/download

TASS Reporting Form